Bupropion in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG). Nondepressed, healthy subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG were randomly assigned to placebo or flexibly dosed bupropion in a 12-week double-blind trial. Outcome measures included the Yale-Brown Obsessive-Compulsive Scale modified for PG, the Gambling Severity Assessment Scale, the Clinical Global Impression Improvement and Severity Scales, the Global Assessment Scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Rating Scale, and the Sheehan Disability Scale. Thirty-nine subjects (28 men, 11 women) were randomized to bupropion (n = 18) or placebo (n = 21). The 2 groups were similar on demographic and clinical measures. There were few differences between the treatment groups on any primary or secondary outcome measure, although subjects in each cell experienced significant improvement. Of subjects with at least 1 postrandomization visit, 35.7% of bupropion and 47.1% of placebo recipients experienced "much" or "very much" improvement on the Clinical Global Impression Improvement Scale. The trial was complicated by a high noncompletion rate (43.6%). Bupropion was well tolerated. Bupropion and placebo recipients did equally well in a short-term trial, with improvement seen as early as the first week of treatment. The high placebo response rate and the high noncompletion rate each reflect the challenge inherent in treating persons with PG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
(1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1184 · Cited by 2,948
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Toward a syndrome model of addiction: Multiple expressions, common etiology
Shaffer, H. J., LaPlante, D. A., LaBrie, R. A., Kidman, R. C., Donato, A. N., & Stanton, M. V. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490905705 · Cited by 682 · cited 1×
“The fact that bupropion is also effective in treating nicotine withdrawal was also intriguing because PG is often thought of as a behavioral addiction.(37) Since starting our RCT, Dannon et al(38,39) have published 2 reports supporting the use of bupropion.”
BackgroundGambling and Related Mental Disorders: A Public Health Analysis
Shaffer, H. J., & Korn, D. A. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140532 · Cited by 538
A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272 · cited 1×
“First, the drug is widely used in the treatment of attention-deficit/hyperactivity disorder (ADHD), and for that reason was hypothesized to be possibly effective in treating PG because both ADHD and subsyndromal ADHD features are common to persons with PG and may be responsible in part for fueling their impulsivity.(2…”
BackgroundLittle Use of Treatment Among Problem Gamblers
Cunningham, J. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.8.1024-a · Cited by 131
Cited by
Hodgins, D. C., Stea, J. N., & Grant, J. E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62185-x · Cited by 452
Potenza, M. N., Balodis, I. M., Derevensky, J., Grant, J. E., Petry, N. M., Verdejo-Garcia, A., & Yip, S. W. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0099-7 · Cited by 437
Impulse Control Disorders: Updated Review of Clinical Characteristics and Pharmacological Management
Schreiber, L., Odlaug, B. L., & Grant, J. E. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00001 · Cited by 290
(2010) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh.2010.22.1.3 · Cited by 262
Dowling, N. A., Merkouris, S. S., & Lorains, F. K. (2016) · Addictive Behaviors · doi:10.1016/j.addbeh.2016.02.012 · Cited by 73
Metadata
- Authors
- Black, D. W., Arndt, S., Coryell, W. H., Argo, T., Forbush, K. T., Shaw, M. C., Perry, P., & Allen, J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-04
- Volume
- 27
- Issue
- 2
- Pages
- 143-150
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2012663535
- Cited by
- 137
- References
- 7
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bupropion in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study. https://app.cochat.ai/papers/10.1097/01.jcp.0000264985.25109.25
- The paper
- Black, D. W., Arndt, S., Coryell, W. H., Argo, T., Forbush, K. T., Shaw, M. C., Perry, P., & Allen, J. (2007). Bupropion in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000264985.25109.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.